Searchable abstracts of presentations at key conferences in endocrinology

ea0004oc24 | Steroid hormone action | SFE2002


Gurnell E , Hunt P , Curran S , Conway C , Huppert F , Herbert J , Chatterjee V

In a double-blind study, 106 patients (44 males, 62 females, age 20-64 years) with Addison's disease, were randomised to receive either 50mg of micronised DHEA or placebo orally daily for 12 months. Psychological and biochemical parameters were measured at baseline, 3 to 6 month intervals and post-washout; bone mineral density (BMD) and body composition were assessed by DEXA at baseline and 12 months.DHEAS levels rose significantly and were maintained th...

ea0010oc9 | Thyroid and pituitary | SFE2005

Association of the thyrotrophin receptor gene (TSHR) with Graves’ disease: evidence from independent UK population based case control and family studies

Brand O , Heward J , Brix T , Carr-Smith J , Connell J , Hegedus L , Hunt P , Robinson B , Wass J , Wiersinga W , Franklyn J , Weetman|S##Gough A

Genetic variants consistently associated with the development of GravesÂ’ disease (GD) have, to date, been general autoimmunity loci including those within the HLA region, the CTLA-4 gene and most recently the PTPN22 gene encoding lymphoid tyrosine phosphatase (LYP). The thyrotophin receptor gene (TSHR) has recently however, been identified as the first GravesÂ’ disease specific susceptibility locus. To further refine association with disease and exclude populat...